ストックスクリーナーアプリを入手
1.43
2.72%
-0.04
前日終値:
$1.47
開ける：
$1.43
24時間の取引高:
52,942
Relative Volume:
0.78
時価総額：
$13.71M
収益：
-
当期純損益:
$-18.98M
株価収益率:
-0.5011
EPS:
-2.8535
ネットキャッシュフロー:
$-14.55M
1週間 パフォーマンス:
-0.69%
1か月 パフォーマンス:
+0.70%
6か月 パフォーマンス:
+3.62%
1年 パフォーマンス:
-32.86%
1日の値動き範囲:
$1.43
$1.50
1週間の範囲:
$1.38
$1.50
52週間の値動き範囲:
$1.17
$2.73
In 8 Bio Inc Stock (INAB) Company Profile
Compare INAB vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.43 | 13.71M | 0 | -18.98M | -14.55M | -2.8535 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-03-18 | 開始されました | Laidlaw | Buy |
| 2022-08-30 | 開始されました | H.C. Wainwright | Buy |
In 8 Bio Inc (INAB) 最新ニュース
FDA grants Orphan Drug Designation to GRI Bio (NASDAQ: GRI) therapy GRI-0621 in IPF - Stock Titan
Adicet Bio (ACET) investors back board nominees, pay and KPMG at 2026 meeting - Stock Titan
Valion Bio (NASDAQ: VBIO) adds $250,000 via Series B preferred share and warrant sale - Stock Titan
Annovis Bio (NYSE: ANVS) holders expand equity plan and set biennial say-on-pay - Stock Titan
INmune Bio (INMB) holders OK larger stock plan and evergreen share increases - Stock Titan
Boundless Bio, Inc. Files 8-K with SEC: Company Details, Stock Info, and Emerging Growth Status Revealed - Minichart
[8-K] Boundless Bio, Inc. Reports Material Event - Stock Titan
Gossamer Bio (NASDAQ: GOSS) swaps most 2027 converts into 2030 debt and equity - Stock Titan
Kyntra Bio, Inc. 8-K SEC Filing Details June 12, 2026 – Company Information, Address, and Stock Listing - Minichart
Kyntra Bio (NASDAQ: KYNB) investors back board, pay and PwC auditor - Stock Titan
BioRestorative Therapies (NASDAQ: BRTX) adds $1M revolver and installs lender-backed directors - Stock Titan
[SCHEDULE 13G] Gossamer Bio, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Palisade Bio (PALI) raises authorized shares to 450M and refreshes equity plans - Stock Titan
Korro Bio (NASDAQ: KRRO) investors back directors, pay and auditor - Stock Titan
[8-K] Instil Bio, Inc. Reports Material Event - Stock Titan
TELA Bio (NASDAQ: TELA) OKs 3.5M-share incentive plan boost - Stock Titan
Climb Bio reports encouraging Phase 1b ITP data; 250 mg cohort shows durable platelet gains - TradingView
Climb Bio (CLYM) details early budoprutug Phase 1b/2a ITP results and risks - Stock Titan
Cabaletta Bio (NASDAQ: CABA) doubles authorized common shares - Stock Titan
[Form 4] Cabaletta Bio, Inc. Insider Trading Activity - Stock Titan
Director at Cabaletta Bio (CABA) receives grant of 22,000 stock options - Stock Titan
Cabaletta Bio (CABA) director receives stock options for 22,000 shares at $3.22 - Stock Titan
Cabaletta Bio (CABA) director Catherine Bollard receives 22,000 stock options at $3.22 - Stock Titan
22,000 options granted to Cabaletta Bio (CABA) director Brun - Stock Titan
[8-K] Bio Green Med Solution, Inc. Reports Material Event - Stock Titan
[Form 4] KYNTRA BIO, INC. Insider Trading Activity - Stock Titan
Kyntra Bio (NASDAQ: FGEN) completes $220M China sale payments - Stock Titan
Climb Bio (CLYM) director receives stock options on 40,000 common shares - Stock Titan
Climb Bio (NASDAQ: CLYM) expands equity plan evergreen to cover pre-funded warrants - Stock Titan
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform - Business Wire
Prudential (NYSE: PRU) holds 24.3M shares of Cabaletta Bio (CABA), 11.4% - Stock Titan
Gossamer Bio, Inc. 8-K Filing June 2026: Annual Meeting Results and Company Information - Minichart
Climb Bio, Inc. Files Form 8-K with SEC – Corporate Information, Stock Details, and Emerging Growth Status - Minichart
Climb Bio (NASDAQ: CLYM) advances CLYM116 toward Phase 2 IgAN trial - Stock Titan
Gossamer Bio (NASDAQ: GOSS) swaps $181M converts for new debt, equity and warrants - Stock Titan
Gossamer Bio (GOSS) holders re-elect directors and approve say-on-pay - Stock Titan
Valion Bio (NASDAQ: VBIO) investors approve major equity plan boost and share issuances - Stock Titan
Cabaletta Bio (CABA) details strong rese-cel data and pivotal plans in myositis, SSc and lupus - Stock Titan
New MRI biomarker backs INmune Bio (NASDAQ: INMB) Alzheimer’s drug - Stock Titan
Gossamer Bio (NASDAQ: GOSS) extends early tender deadline in major convertible note exchange - Stock Titan
Nuvation Bio Inc. Files Form 8-K with SEC Detailing Company Information and Annual Meeting Results - Minichart
Nuvation Bio (NUVB) shareholders elect directors, ratify KPMG and approve pay - Stock Titan
Passage Bio (NASDAQ: PASG) ends Gemma deal, pays $2.3M to exit lease - Stock Titan
Q32 Bio (NASDAQ: QTTB) prices $55M stock and pre-funded warrant sale - Stock Titan
Bio-Path (OTC: BPTH) unveils crypto treasury plan and $57.9M judgment tie - Stock Titan
Passage Bio, Inc. 2026 Annual Meeting Results: Stockholder Votes and Key Corporate Information (Form 8-K) - Minichart
Passage Bio (NASDAQ: PASG) holders choose annual say-on-pay at 2026 meeting - Stock Titan
GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
VBIO SEC FilingsValion Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Annovis Bio (NYSE: ANVS) prices $15M common stock and warrant offering - Stock Titan
Korro Bio (NASDAQ: KRRO) unveils KRRO-111 AATD RNA editing data - Stock Titan
In 8 Bio Inc (INAB) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):